Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Rizvi, Naiyer A
  • Gettinger, Scott N
  • Goldman, Jonathan W
  • Hellmann, Matthew D
  • Chow, Laura Q
  • Juergens, Rosalyn
  • Borghaei, Hossein
  • Brahmer, Julie R
  • Shen, Yun
  • Harbison, Christopher
  • Nathan, Faith
  • Ready, Neal
  • Antonia, Scott J

publication date

  • September 1, 2015